
Theravance Biopharma TBPH
$ 16.79
0.27%
Annual report 2025
added 03-23-2026
Theravance Biopharma Total Current Liabilities 2011-2026 | TBPH
Annual Total Current Liabilities Theravance Biopharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 38.3 M | 32.1 M | 24.8 M | 28.7 M | 58.6 M | 124 M | 112 M | 98.6 M | 62.6 M | 49.3 M | 49.5 M | 41.3 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 124 M | 24.8 M | 59.9 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aptorum Group Limited
APM
|
4.59 M | $ 0.87 | -0.11 % | $ 6.4 M | ||
|
Aquestive Therapeutics
AQST
|
47.6 M | $ 4.18 | 1.95 % | $ 447 M | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
534 M | $ 9.76 | 1.77 % | $ 631 M | ||
|
AgeX Therapeutics
AGE
|
3.56 M | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
576 M | - | - | $ 866 M | ||
|
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B | ||
|
AlloVir
ALVR
|
9.71 M | - | 4.14 % | $ 49.1 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
395 M | $ 21.99 | -2.05 % | $ 3.64 B | ||
|
Cerus Corporation
CERS
|
101 M | $ 2.89 | 42.45 % | $ 551 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | ||
|
Athira Pharma
ATHA
|
47.5 M | - | - | $ 269 M | ||
|
Applied Molecular Transport
AMTI
|
15.1 M | - | - | $ 10.1 M | ||
|
Ayala Pharmaceuticals
AYLA
|
7.54 M | - | - | $ 7.46 M | ||
|
Atreca
BCEL
|
16.3 M | - | -11.76 % | $ 5.79 M | ||
|
Berkeley Lights
BLI
|
45.5 M | - | -7.31 % | $ 87 M | ||
|
Calithera Biosciences
CALA
|
14 M | - | -10.95 % | $ 876 K | ||
|
Advaxis
ADXS
|
25 M | - | -9.65 % | $ 45.9 M | ||
|
CymaBay Therapeutics
CBAY
|
36.8 M | - | - | $ 3.45 B | ||
|
ChemoCentryx
CCXI
|
63 M | - | - | $ 3.74 B | ||
|
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - | ||
|
Caladrius Biosciences
CLBS
|
5.61 M | - | -16.75 % | $ 25.8 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
9.38 M | - | - | $ 231 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | ||
|
Aeglea BioTherapeutics
AGLE
|
58.7 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
100 M | - | - | $ 2.18 B | ||
|
AIkido Pharma
AIKI
|
1.61 M | - | 1.93 % | $ 17.4 M | ||
|
Dynavax Technologies Corporation
DVAX
|
78.6 M | - | - | $ 2.02 B | ||
|
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
36.6 M | - | - | $ 28.6 M | ||
|
Editas Medicine
EDIT
|
46.2 M | $ 2.88 | -4.17 % | $ 256 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
2.73 M | $ 2.97 | -6.9 % | $ 4.89 M | ||
|
Edesa Biotech
EDSA
|
1.83 M | $ 18.1 | -0.96 % | $ 57.9 M | ||
|
Eiger BioPharmaceuticals
EIGR
|
53.3 M | - | -9.21 % | $ 2.55 M | ||
|
Eloxx Pharmaceuticals
ELOX
|
23.1 M | - | -5.68 % | $ 8.28 M | ||
|
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | ||
|
Applied Therapeutics
APLT
|
71.2 M | - | - | $ 8.42 M | ||
|
Aptose Biosciences
APTO
|
9.31 M | - | -45.71 % | $ 1.2 M |